CJC-1295 Without DAC (5 mg)

What is CJC-1295 - No DAC (5mg)?

CJC-1295 - No DAC (5mg) is a synthetic 29-amino acid analog of growth hormone–releasing hormone (GHRH 1-29). It is classified among muscle growth and performance peptides and is designed as a modified GHRH fragment with enhanced stability, lacking a Drug Affinity Complex (DAC).

• Synonyms: MOD-GRF(1-29), CJC-1295 without DAC, modgrf, tetrasubstituted GRF, modified GRF
• CAS Number: 863288-34-0
• Chemical Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: 3367.9 g/mol
• Peptide Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg

The peptide sequence includes a D-Ala substitution at position 2, which has been studied for its role in reducing rapid enzymatic degradation. Research-grade preparations typically demonstrate purity ≥99% by HPLC and are used in experimental models evaluating somatotropic signaling dynamics.

What are the key features of CJC-1295 - No DAC (5mg)?

CJC-1295 - No DAC (5mg) is supplied as a lyophilized powder to preserve peptide integrity and ensure precise reconstitution for controlled laboratory protocols. Key features include:

• 5 mg lyophilized vial for flexible experimental design
• Purity ≥99%, verified by HPLC and mass spectrometry (MS)
• 29-residue modified GHRH analog with D-Ala2 substitution
• Non-DAC format for short-acting signaling studies
• Investigated in pituitary cell assays and endocrine research models
• Batch-specific Certificate of Analysis (COA) available
• The absence of DAC conjugation results in shorter pharmacokinetic activity compared to long-acting variants, making it suitable for studies of transient receptor activation

For laboratory research use only.

How is CJC-1295 - No DAC (5mg) synthesized?

CJC-1295 - No DAC is synthetically produced using solid-phase peptide synthesis (SPPS). This method enables controlled assembly of the 29-amino acid sequence, including specific substitutions that enhance structural stability and receptor interactions compared to native GHRH (1-29). The tetrasubstituted configuration has been studied for improved resistance to enzymatic cleavage while maintaining biological activity in experimental systems. After synthesis, the peptide undergoes purification by reverse-phase HPLC to achieve high purity. Identity confirmation and molecular weight verification (3367.9 g/mol) are performed using mass spectrometry (MS). Analytical documentation typically includes chromatograms, mass spectra, and purity percentages to support reproducibility in receptor-binding and signaling assays.

What is CJC-1295 - No DAC (5mg) being studied for? What are its possible benefits?

CJC-1295 - No DAC has been studied for its ability to stimulate growth hormone release in preclinical models by activating GHRH pathways. Research in rodent and in vitro pituitary systems has evaluated its effects on growth hormone (GH) secretion kinetics, adenylate cyclase activation, and downstream signaling events. Areas of investigation include:

• Transient stimulation of GH release in animal models
• Modulation of insulin-like growth factor-1 (IGF-1) levels in experimental settings
• Evaluation of anabolic signaling pathways
• Assessment of metabolic and protein synthesis markers
• Structure–activity relationship studies among GHRH analogs

Because this version lacks DAC conjugation, it is being studied specifically for short-duration endocrine responses rather than for prolonged systemic exposure. Observed effects are limited to controlled experimental models and do not necessarily translate into established clinical outcomes.

How does CJC-1295 - No DAC (5mg) work in research studies?

In laboratory models, CJC-1295 - No DAC is studied for its interaction with GHRH receptors on pituitary somatotroph cells. Activation of this pathway has been associated with stimulation of adenylate cyclase activity and increased intracellular cyclic AMP (cAMP) levels. Elevated cAMP may activate protein kinase A (PKA), influencing transcriptional processes linked to growth hormone synthesis and secretion. Because the peptide does not contain a Drug Affinity Complex (DAC), its activity profile is characterized by a relatively rapid onset and shorter duration compared to DAC-linked analogs. This makes it useful in research examining acute signaling kinetics, feedback mechanisms, and pulsatile endocrine regulation.

What dosing information exists for CJC-1295 - No DAC (5mg)?

Dosing information for CJC-1295 - No DAC is derived from preclinical and in vitro studies. In rodent models, GHRH analogs of this class have been studied at doses ranging from approximately 10 to 100 µg/kg to evaluate acute growth hormone responses. In pituitary cell culture systems, concentrations in the 1–100 nM range have been used to measure:

• cAMP accumulation
• Growth hormone secretion
• Signal transduction activity over short time frames (15–60 minutes)

Peak GH responses in animal studies have been reported within approximately 30 minutes following administration, with activity lasting roughly 1–2 hours due to the absence of DAC modification. There are no approved or validated human dosing guidelines for CJC-1295 - No DAC (5mg).

How should CJC-1295 - No DAC (5mg) be stored and handled?

Proper storage and handling are essential to maintain peptide stability:

• Store lyophilized powder at ≤–20 °C for long-term storage
• Protect from light and moisture
• Shelf life of up to 24 months under recommended conditions
• Short-term room temperature exposure during transport is acceptable
• Store at 2–8 °C for short-term use
• Use aseptic laboratory technique during reconstitution

Adherence to these guidelines helps preserve structural integrity and analytical consistency.

Where can I read more research about CJC-1295 - No DAC (5mg)?

The following peer-reviewed publications provide context for GHRH analog research:

1. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. Published 2021 Nov 22. doi:10.3390/molecules26227053
2. Frohman MA, Downs TR, Chomczynski P, Frohman LA. Cloning and characterization of mouse growth hormone-releasing hormone (GRH) complementary DNA: increased GRH messenger RNA levels in the growth hormone-deficient lit/lit mouse. Mol Endocrinol. 1989;3(10):1529-1536. doi:10.1210/mend-3-10-1529
3. Campbell RM, Bongers J, Felix AM. Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues. Biopolymers. 1995;37(2):67-88. doi:10.1002/bip.360370204
4. Zarandi M, Csernus V, Bokser L, Bajusz S, Groot K, Schally AV. Synthesis and in vitro and in vivo activity of analogs of growth hormone-releasing hormone (GH-RH) with C-terminal agmatine. Int J Pept Protein Res. 1990;36(6):499-505. doi:10.1111/j.1399-3011.1990.tb00988.x

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.